Country: United Kingdom
Language: English
Source: MHRA (Medicines & Healthcare Products Regulatory Agency)
Clomifene citrate
Sigma Pharmaceuticals Plc
G03GB02
Clomifene citrate
50mg
Oral tablet
Oral
No Controlled Drug Status
Valid as a prescribable product
BNF: 06050100
PACKAGE LEAFLET: INFORMATION FOR THE USER CLOMID® 50MG TABLETS clomifene citrate Is this leaflet hard to see or read? Phone no - 08453727101 for help READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor or pharmacist. • This medicine has been prescribed to you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. • If you get any side effects, talk to your pharmacist. This includes any possible side effects not listed in this leaflet (see section 4). WHAT IS IN THIS LEAFLET: 1. What Clomid is and what it is used for 2. What you need to know before you take Clomid 3. How to take Clomid 4. Possible side effects 5. How to store Clomid 6. Contents of the pack and other information 1. WHAT CLOMID IS AND WHAT IT IS USED FOR Clomid contains a medicine called clomifene citrate. This belongs to a group of medicines called ovulation stimulants. It works by stimulating the release of eggs from the ovary (ovulation). Clomid is used for some types of infertility, in women who are not ovulating properly. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE CLOMID BEFORE YOU TAKE THE MEDICINE TALK TO YOUR DOCTOR ABOUT THE RISKS OF: Becoming pregnant with more than one child at the same time (multiple pregnancies) Pregnancies where the baby grows outside of the womb (ectopic) A possible increased risk of ovarian cancer Any pregnancy could lead to birth defects or miscarriage. This can happen even if you are not taking Clomid. You should talk to your doctor about the possible risks before you take Clomid. DO NOT TAKE THIS MEDICINE AND TELL YOUR DOCTOR IF: You are allergic (hypersensitive) to clomifene or any of the other ingredients of Clomid (listed in Section 6 below). Signs of an allergic reaction include: a rash, swallowing or breathing problems, swelling of your lips, face, throat or tongue You have or e Read the complete document
1. NAME OF THE MEDICINAL PRODUCT Clomid™ 50mg Tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Clomifene Citrate 50mg_ _ 3. PHARMACEUTICAL FORM Tablet 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Clomid 50mg Tablets 50mg Tablets (Clomifene Citrate BP) is indicated for the treatment of ovulatory failure in women desiring pregnancy. Clomid 50mg Tablets 50mg Tablets is indicated only for patients in whom ovulatory dysfunction is demonstrated. Other causes of infertility must be excluded or adequately treated before giving Clomid 50mg Tablets 50mg Tablets. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Route of Administration Oral Adults Only: The recommended dose for the first course of Clomid 50mg Tablets 50mg Tablets (Clomifene Citrate BP) is 50mg (1 tablet) daily for 5 days. Therapy may be started at any time in the patient who has had no recent uterine bleeding. If progestin-induced bleeding is planned, or if spontaneous uterine bleeding occurs before therapy, the regimen of 50mg daily for 5 days should be started on or about the fifth day of the cycle. When ovulation occurs at this dosage, there is no advantage to increasing the dose in subsequent cycles of treatment. If ovulation appears not to have occurred after the first course of therapy, a second course of 100mg daily (two 50mg tablets given as a single daily dose) for 5 days should be given. This course may be started as early as 30 days after the previous one. Increase of the dosage or duration of therapy beyond 100mg/day for 5 days should not be undertaken. The majority of patients who are going to respond will respond to the first course of therapy, and 3 courses should constitute an adequate therapeutic trial. If ovulatory menses have not yet occurred, the diagnosis should be re-evaluated. Treatment beyond this is not recommended in the patient who does not exhibit evidence of ovulation. _Long-term cyclic therapy. _ _ _ Not recommended. The relative safety of long-term cyclic therapy has not been conclusively demonstrated and, since the majorit Read the complete document